This is related to the BFI-751, the proposed biosimilar product to Telara (ustekinumab).
Aurobindo Pharma said the decision is aligned with CuraTeQ’s strategic portfolio prioritisation.
Aurobindo Pharma also clarified that the termination, effective December 27, 2025, was reached by mutual consent and is not expected to have any material impact on its broader biosimilars strategy.
As per the arrangement, BioFactura would receive a licence fee and milestone payments.
Last week, Aurobindo Pharma’s other wholly-owned subsidiary Helix Healthcare BV entered a binding agreement to acquire an additional 20% stake in Luoxin Aurovitas Pharma (Chengdu) Co. Ltd., China for $5.125 million.
The transaction will raise Helix’s ownership in the joint venture to 50%. At present, Luoxin Aurovitas is a 30:70 joint venture between Helix and Shangdong Luoxin Pharmaceutical Group Stock Co. Ltd.
The acquisition will be completed within the next three months.
Shares of Aurobindo Pharma were trading flat at ₹1,207.3 apiece around 10.15 am on Monday. The stock has declined 10.8% this year, so far.
Also Read: Defence stocks HAL, BDL, others in focus on Monday ahead of Defence Acquisition Council meet
